Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.

Summary: Imagine trying to build a modern smartphone using a manual written for a flip phone from 2003. That is essentially the challenge researchers face when developing new treatments for Rheumatoid Arthritis (RA) in Europe. The official rules for testing drugs haven't changed since 2003, but the medicine certainly has. We now have powerful "biologic" drugs that can stop joint damage, and we know that treating patients earlier and monitoring them more closely yields better results. To fix this disconnect, a group of experts (GREES) has gathered to update the regulatory rulebook. Their goal is to ensure that future clinical trials reflect modern science, ultimately bringing safer and more effective treatments to patients faster.